X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES AJANTA PHARMA JUBILANT LIFE SCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 15.3 20.1 76.2% View Chart
P/BV x 4.5 4.7 97.1% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
AJANTA PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1871,818 10.3%   
Low Rs651,106 5.9%   
Sales per share (Unadj.) Rs364.3239.5 152.1%  
Earnings per share (Unadj.) Rs6.852.8 13.0%  
Cash flow per share (Unadj.) Rs24.559.5 41.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %2.40-  
Book value per share (Unadj.) Rs164.9230.0 71.7%  
Shares outstanding (eoy) m159.2888.77 179.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.1 5.7%   
Avg P/E ratio x18.427.7 66.4%  
P/CF ratio (eoy) x5.124.6 20.9%  
Price / Book Value ratio x0.86.4 12.0%  
Dividend payout %43.80-   
Avg Mkt Cap Rs m20,061129,782 15.5%   
No. of employees `0006.26.8 91.0%   
Total wages/salary Rs m11,0523,765 293.6%   
Avg. sales/employee Rs Th9,383.03,128.4 299.9%   
Avg. wages/employee Rs Th1,786.9554.0 322.5%   
Avg. net profit/employee Rs Th176.3689.7 25.6%   
INCOME DATA
Net Sales Rs m58,03421,258 273.0%  
Other income Rs m191242 78.9%   
Total revenues Rs m58,22421,499 270.8%   
Gross profit Rs m5,7866,584 87.9%  
Depreciation Rs m2,812596 471.8%   
Interest Rs m3,2374 78,956.1%   
Profit before tax Rs m-726,226 -1.2%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,539 45.2%   
Profit after tax Rs m1,0904,686 23.3%  
Gross profit margin %10.031.0 32.2%  
Effective tax rate %-965.924.7 -3,906.9%   
Net profit margin %1.922.0 8.5%  
BALANCE SHEET DATA
Current assets Rs m29,28012,236 239.3%   
Current liabilities Rs m38,9123,461 1,124.5%   
Net working cap to sales %-16.641.3 -40.2%  
Current ratio x0.83.5 21.3%  
Inventory Days Days8460 140.1%  
Debtors Days Days5184 60.0%  
Net fixed assets Rs m55,71211,140 500.1%   
Share capital Rs m155177 87.3%   
"Free" reserves Rs m20,96820,237 103.6%   
Net worth Rs m26,26520,414 128.7%   
Long term debt Rs m17,16910 169,988.1%   
Total assets Rs m88,60624,486 361.9%  
Interest coverage x1.01,519.4 0.1%   
Debt to equity ratio x0.70 132,117.8%  
Sales to assets ratio x0.70.9 75.4%   
Return on assets %4.919.2 25.5%  
Return on equity %4.223.0 18.1%  
Return on capital %11.630.5 37.9%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00411,667 188.6%   
Fx outflow Rs m11,7491,616 727.3%   
Net fx Rs m10,25510,052 102.0%   
CASH FLOW
From Operations Rs m8,0262,854 281.2%  
From Investments Rs m-1,744-2,604 67.0%  
From Financial Activity Rs m-4,447-2 222,370.0%  
Net Cashflow Rs m1,834248 739.4%  

Share Holding

Indian Promoters % 45.6 73.8 61.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 1.6 561.3%  
FIIs % 21.2 7.6 278.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 17.0 124.1%  
Shareholders   23,815 20,968 113.6%  
Pledged promoter(s) holding % 15.9 4.4 361.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Dec 13, 2018 03:35 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS